HALO FY 2024 Earnings Report — Halozyme Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

Halozyme Therapeutics, Inc.HALO

FY 2024 Earnings

Reported February 18, 2025

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2024	Prior Q	FY 2023	QoQ Change	YoY Change
Revenue	$1.0B	—	$829M	—	22.4%
Op. Income	$551M	—	$338M	—	63.4%
Gross Margin	84.3%	—	76.8%	—	7.5pp
Net Margin	43.7%	—	34.0%	—	9.8pp
EPS (Diluted)	$3.43	—	$2.10	—	63.3%
Free Cash Flow	$468M	—	$373M	—	25.5%

Revenue Flow

Item	Amount
REVENUE	$1.0B
Cost of Revenue	$159M
GROSS PROFIT	$856M
R&D Expenses	$79M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$154M
Other Expenses	$71M
Operating Expenses	$304M
Cost & Expenses	$464M
OPERATING INCOME	$551M
Interest Income	$0
Interest Expense	$18M
Other Income/Expenses	$6M
INCOME BEFORE TAX	$557M
Income Tax Expense	$113M
Net Income from Continuing Ops	$444M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$444M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$444M
D&A	$81M
EBIT	$575M
EBITDA	$657M
EPS	$4
EPS Diluted	$3

Income Statement

Item	Amount
REVENUE	$1.0B
Cost of Revenue	$159M
GROSS PROFIT	$856M
R&D Expenses	$79M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$154M
Other Expenses	$71M
Operating Expenses	$304M
Cost & Expenses	$464M
OPERATING INCOME	$551M
Interest Income	$0
Interest Expense	$18M
Other Income/Expenses	$6M
INCOME BEFORE TAX	$557M
Income Tax Expense	$113M
Net Income from Continuing Ops	$444M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$444M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$444M
D&A	$81M
EBIT	$575M
EBITDA	$657M
EPS	$4
EPS Diluted	$3

Cash Flow Statement

Item	Amount
Net Income	$444M
Depreciation & Amortization	$89M
Stock-Based Compensation	$43M
Deferred Income Tax	$0
Other Non-Cash Items	$39M
Change in Working Capital	-$136M
OPERATING CASH FLOW	$479M
Capital Expenditure	-$11M
Acquisitions (Net)	$0
Purchases of Investments	$0
Sales/Maturities of Investments	$0
Other Investing Activities	-$252M
NET CASH FROM INVESTING	-$263M
Net Debt Issuance	$0
Common Stock Repurchased	-$250M
Common Dividends Paid	$0
Other Financing Activities	$31M
NET CASH FROM FINANCING	-$219M
FREE CASH FLOW	$468M
Net Change in Cash	-$3M

Balance Sheet

Item	Amount
Cash & Equivalents	$116M
Short-Term Investments	$480M
Net Receivables	$308M
Inventory	$142M
Other Current Assets	$39M
TOTAL CURRENT ASSETS	$1.1B
PP&E (Net)	$75M
Goodwill	$417M
Intangible Assets	$402M
Long-Term Investments	$0
Tax Assets	$4M
Other Non-Current Assets	$81M
TOTAL NON-CURRENT ASSETS	$978M
TOTAL ASSETS	$2.1B
Account Payables	$10M
Short-Term Debt	$0
Deferred Revenue	$0
Other Current Liabilities	$0
TOTAL CURRENT LIABILITIES	$139M
Long-Term Debt	$1.5B
Deferred Revenue NC	$0
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$55M
TOTAL NON-CURRENT LIABILITIES	$1.6B
TOTAL LIABILITIES	$1.7B
Common Stock	$123.0K
Additional Paid-In Capital	$0
Retained Earnings	$360M
Treasury Stock	$0
Accum. Other Comp. Income	$4M
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$364M
Minority Interest	$0
TOTAL EQUITY	$364M
TOTAL LIABILITIES & EQUITY	$2.1B
Total Debt	$1.5B
Net Debt	$1.4B